Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 79.67 -0.86 (-1.07%) Market Cap: 15.12 Bil Enterprise Value: 15.17 Bil PE Ratio: 74.44 PB Ratio: 2.98 GF Score: 76/100

Biomarin Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2020 / 06:10PM GMT
Release Date Price: $106
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

Good afternoon. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. I'm pleased to have BioMarin here with us this afternoon. And with us, we have J.J. Bienaimé, Chairman and CEO; Hank Fuchs, President, Worldwide Research & Development; and Brian Mueller, Acting CFO.

And with that, I'll turn it over to you, J.J., in the case that you want to make some opening remarks here.

Jean;Jacques BienaimÃ;BioMarin Pharmaceutical Inc.;Chairman;CEO

©,-&

So thank you, Salveen. We are very happy to participate in your June conference for the seventh year in a row, even if we cannot talk in person. So it is no coincidence that BioMarin is at a significant inflection point in 2020. We have been growing the company for many years, honing our R&D platform, advancing our manufacturing capabilities, expanding our global commercial footprint and working with the health authorities around the world to develop essential medicine

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot